Grifols Negotiates To Take Control Of Leader In Blood Products In China
The Spanish blood products company could invest 5 bn$ in the Chinese pharmaceutical company Shanghai RAAS Blood Products, leader in China, which specialises in the investigation, production and sales of plasma products. The operation would be formalised in Q219. Grifols would reinforce its position in China and would reduce its dependence on the US.